周氏红鹿方联合甲磺酸多沙唑嗪缓释片治疗Ⅲ型慢性前列腺炎(湿热瘀阻型)的临床疗效观察  

The clinical efficacy observation of Zhou′s Honglu Prescription combined with doxazosin mesylate sustained-release tablets in the treatment of typeⅢchronic prostatitis(damp-heat stasis type)

作　　者：宋子希 曹宏文[1] 陈磊[1,2,3] 高人杰 王丹 白慧明 李海滨 吴效通 赵文洋 冯懿赓 SONG Zixi;CAO Hongwen;CHEN Lei;GAO Renjie;WANG Dan;BAI Huiming;LI Haibin;WU Xiaotong;ZHAO Wenyang;FENG Yigeng(Department of Urology and Andrology,Longhua Hospital Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;Shanghai Clinical Demonstration Base of Urology of Traditional Chinese Medicine,Shanghai 200032,China;Shanghai Famous Zhou Zhiheng Urology Studio of Traditional Chinese Medicine,Shanghai 200032,China)

机构地区：[1]上海中医药大学附属龙华医院泌尿外科/男科,上海200032 [2]上海市中医泌尿男科临床示范基地,上海200032 [3]上海市名中医周智恒教授泌尿男科工作室,上海200032

出　　处：《中国性科学》2024年第8期107-111,共5页Chinese Journal of Human Sexuality

基　　金：国家自然科学基金常规面上项目(82174199)。

摘　　要：目的探讨周氏红鹿方联合甲磺酸多沙唑嗪缓释片治疗Ⅲ型慢性前列腺炎(湿热瘀阻型)的临床效果。方法选取2021年7月至2023年3月上海中医药大学附属龙华医院收治的80例Ⅲ型慢性前列腺炎(湿热瘀阻型)患者作为研究对象。采用随机数字表法分为治疗组和对照组,每组40例。对照组采用甲磺酸多沙唑嗪缓释片治疗,治疗组在对照组基础上联合周氏红鹿方治疗。比较两组治疗前后美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)及前列腺液常规水平,比较两组临床疗效。结果治疗后,两组NIH-CPSI评分较治疗前显著降低,且治疗组低于对照组,差异具有统计学意义(P<0.05)。两组总有效率比较,差异具有统计学意义(P<0.05)。治疗后,两组白细胞计数(WBC)水平均低于治疗前,且治疗组低于对照组,差异具有统计学意义(P<0.05);治疗后,两组卵磷脂小体水平均增加,且治疗组大于对照组,差异具有统计学意义(P<0.05)。结论周氏红鹿方联合甲磺酸多沙唑嗪缓释片治疗Ⅲ型慢性前列腺炎(湿热瘀阻型)较单独西药的疗效更好,可显著缓解患者的临床症状,改善前列腺液常规水平。Objective To investigate the clinical effect of Zhou′s Honglu Prescription combined with doxazosin mesylate sustained-release tablets in the treatment of typeⅢchronic prostatitis(damp-heat stasis type).Methods A total of 80 patients with typeⅢchronic prostatitis(damp-heat stasis type)admitted to Longhua Hospital Shanghai University of Traditional Chinese Medicine from July 2021 to March 2023 were selected as study subjects.Randomized numerical table method was used to divide them into treatment group and control group,with 40 cases in each group.The control group was treated with doxazosin mesylate sustained-release tablets,and the treatment group was combined with Zhou′s Honglu Prescription the basis of the control group.The national institutes of health chronic prostatitis symptom index(NIH-CPSI)and the conventional level of prostate fluid were compared between the two groups before and after treatment,and the clinical efficacy of the two groups was compared.Results After treatment,the NIH-CPSI scores of the two groups were significantly lower than before treatment,and the treatment group was lower than the control group,with statistically significant differences(P<0.05).The total effective rate of the two groups was compared,and the difference was statistically significant(P<0.05).After treatment,the white blood cell count(WBC)levels of two groups were lower than before treatment,and the treatment group was lower than the control group,with statistically significant differences(P<0.05);after treatment,the levels of lecithin microsomes increased in two groups,and the treatment group was larger than the control group,with statistically significant differences(P<0.05).Conclusions Zhou′s Honglu Prescription combined with doxazosin mesylate sustained-release tablets was more effective than western medicine alone in treating typeⅢchronic prostatitis(damp-heat stasis type),which can significantly relieve patients′clinical symptoms and improve the routine level of prostatic fluid.

关 键 词：周氏红鹿方 甲磺酸多沙唑嗪缓释片 Ⅲ型慢性前列腺炎 湿热瘀阻型 临床疗效 

分 类 号：R697[医药卫生—泌尿科学] R275[医药卫生—外科学]